-+ 0.00%
-+ 0.00%
-+ 0.00%

COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS

Reuters·12/18/2025 13:00:05

Please log in to view news